Zhang Jie, Shi Yaling, Zheng Yueqin, Pan Chengcheng, Yang Xiaoying, Dou Taoyan, Wang Binghe, Lu Wen
School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, 710061, P.R. China.
Department of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, Georgia 30303, USA.
Oncotarget. 2017 Aug 7;8(40):68242-68251. doi: 10.18632/oncotarget.20021. eCollection 2017 Sep 15.
Functionalized nanoparticles (NPs) are usually used to enhance cellular penetration for targeted drug delivery that can improve efficacy and reduce side effects. However, it is difficult to exploit intracellular targets for similar delivery applications. Herein we describe the targeted delivery of functionalized NPs by homing in on an intracellular target, histone deacetylases (HDACs). Specifically, a modified poly-lactide-co-glycolideacid (FPLGA) was yielded by conjugation with an HDAC inhibitor. Subsequently, FPLGA was used to prepare functionalized FPLGA NPs. Compared to unmodified NPs, FPLGA NPs were more efficiently uptaken or retained by MCF-7 cells and showed longer retention time intracellular. fluorescence imaging also revealed that they had a higher accumulation and a slower elimination than unmodified NPs. FPLGA NPs loaded with paclitaxel exhibited superior anticancer efficacy compared with unmodified NPs. These results offer a promising approach for intracellular drug delivery through elevating the concentration of NPs.
功能化纳米颗粒(NPs)通常用于增强细胞穿透能力,以实现靶向药物递送,从而提高疗效并减少副作用。然而,在类似的递送应用中,难以利用细胞内靶点。在此,我们描述了通过靶向细胞内靶点组蛋白去乙酰化酶(HDACs)来实现功能化纳米颗粒的靶向递送。具体而言,通过与HDAC抑制剂共轭制备了一种改性聚乳酸-羟基乙酸共聚物(FPLGA)。随后,用FPLGA制备功能化FPLGA纳米颗粒。与未改性的纳米颗粒相比,FPLGA纳米颗粒被MCF-7细胞更有效地摄取或保留,并且在细胞内显示出更长的保留时间。荧光成像还显示,与未改性的纳米颗粒相比,它们具有更高的积累和更慢的消除速度。负载紫杉醇的FPLGA纳米颗粒与未改性的纳米颗粒相比表现出优异的抗癌疗效。这些结果为通过提高纳米颗粒浓度进行细胞内药物递送提供了一种有前景的方法。